

Antonella Tufano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8329321/publications.pdf>

Version: 2024-02-01

69
papers

1,548
citations

304743

22
h-index

330143

37
g-index

70
all docs

70
docs citations

70
times ranked

2283
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1297-1302.	3.8	129
2	Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study. <i>Oncologist</i> , 2017, 22, 601-608.	3.7	108
3	Treatment of hemophilia: a review of current advances and ongoing issues. <i>Journal of Blood Medicine</i> , 2010, 1, 183.	1.7	89
4	Acquired Inhibitors of Coagulation Factors: Part I—Acquired Hemophilia A. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 433-446.	2.7	86
5	Inherited Thrombophilia: Implications for Prevention and Treatment of Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 683-694.	2.7	75
6	Cardiovascular risk factors and outcome in patients with retinal vein occlusion. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 16-22.	2.1	65
7	High prevalence of nonalcoholic fatty liver in patients with idiopathic venous thromboembolism. <i>World Journal of Gastroenterology</i> , 2010, 16, 6119.	3.3	57
8	Bleeding and Thrombosis in Multiple Myeloma and Related Plasma Cell Disorders. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 929-945.	2.7	57
9	Oral Anticoagulant Drugs and the Risk of Osteoporosis: New Anticoagulants Better than Old?. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 382-388.	2.7	54
10	Eculizumab in pregnancy: a narrative overview. <i>Journal of Nephrology</i> , 2019, 32, 17-25.	2.0	46
11	Prevention of Venous Thromboembolism in Medical Patients with Thrombocytopenia or with Platelet Dysfunction: A Review of the Literature. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 267-274.	2.7	44
12	Italian intersociety consensus on DOAC use in internal medicine. <i>Internal and Emergency Medicine</i> , 2017, 12, 387-406.	2.0	44
13	Arterial Ischemic Events Are a Major Complication in Cancer Patients with Venous Thromboembolism. <i>American Journal of Medicine</i> , 2018, 131, 1095-1103.	1.5	41
14	The Infectious Burden in Atherothrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 515-523.	2.7	39
15	Ensuring medication adherence with direct oral anticoagulant drugs. <i>Thrombosis Research</i> , 2014, 133, 699-704.	1.7	39
16	Preventing Postsurgical Venous Thromboembolism: Pharmacological Approaches. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 252-266.	2.7	38
17	Outcomes during anticoagulation in patients with symptomatic vs. incidental splanchnic vein thrombosis. <i>Thrombosis Research</i> , 2018, 164, 69-74.	1.7	35
18	The association of adjusted Global Antiphospholipid Syndrome Score (aGAPSS) with cardiovascular disease in subjects with antiphospholipid antibodies. <i>Atherosclerosis</i> , 2018, 278, 60-65.	0.8	33

#	ARTICLE	IF	CITATIONS
19	Identifying high-risk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update. <i>Internal and Emergency Medicine</i> , 2012, 7, 9-13.	2.0	32
20	Subclinical atherosclerosis in asymptomatic carriers of persistent antiphospholipid antibodies positivity: A cross-sectional study. <i>International Journal of Cardiology</i> , 2019, 274, 1-6.	1.7	32
21	Venous Thromboembolism in COVID-19 Compared to Non-COVID-19 Cohorts: A Systematic Review with Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4925.	2.4	27
22	Speckle tracking echocardiography in patients with systemic lupus erythematosus: A meta-analysis. <i>European Journal of Internal Medicine</i> , 2020, 73, 16-22.	2.2	26
23	Mesoglycan: Clinical Evidences for Use in Vascular Diseases. <i>International Journal of Vascular Medicine</i> , 2010, 2010, 1-8.	1.0	23
24	Spontaneous Muscle Hematoma in Patients with COVID-19: A Systematic Literature Review with Description of an Additional Case Series. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 100-108.	2.7	21
25	Acquired Haemophilia A in the Elderly: Case Reports. <i>Current Gerontology and Geriatrics Research</i> , 2010, 2010, 1-5.	1.6	19
26	Cardiac Manifestations of Antiphospholipid Syndrome: Clinical Presentation, Role of Cardiac Imaging, and Treatment Strategies. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 468-477.	2.7	19
27	Inferior Vena Cava Agenesis and Deep Vein Thrombosis in the Young: A Review of the Literature and Local Experience. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 827-835.	2.7	18
28	Left ventricular diastolic abnormalities other than valvular heart disease in antiphospholipid syndrome: An echocardiographic study. <i>International Journal of Cardiology</i> , 2018, 271, 366-370.	1.7	17
29	Inferior vena cava agenesis in patients with lower limb deep vein thrombosis in the RIETE registry. When and why to suspect. <i>International Journal of Cardiology</i> , 2020, 305, 115-119.	1.7	16
30	The use of nonselective beta blockers is a risk factor for portal vein thrombosis in cirrhotic patients. <i>Saudi Journal of Gastroenterology</i> , 2018, 24, 25.	1.1	15
31	HELLP syndrome and its relation with the antiphospholipid syndrome. <i>Blood Transfusion</i> , 2014, 12, 114-8.	0.4	14
32	Position paper of the Italian Society of Internal Medicine (SIMI) on prophylaxis and treatment of venous thromboembolism in patients with cancer. <i>Internal and Emergency Medicine</i> , 2019, 14, 21-38.	2.0	13
33	Venous Thromboembolism in Patients with Liver Cirrhosis: Findings from the RIETE (Registro) Tj ETQq1 1 0.784314 rgBT /Overlock 10 2019, 45, 793-801.	2.7	12
34	Risk factors and recurrent thrombotic episodes in patients with cerebral venous thrombosis. <i>Blood Transfusion</i> , 2014, 12 Suppl 1, s337-42.	0.4	12
35	Cardiovascular events in patients with antiphospholipid antibodies: Strategies of prevention. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010, 20, 217-223.	2.6	10
36	The Impact of Risk-Adjusted Heparin Regimens on the Outcome of Patients with COVID-19 Infection. A Prospective Cohort Study. <i>Viruses</i> , 2021, 13, 1720.	3.3	9

#	ARTICLE	IF	CITATIONS
37	Cyclic supplementation of 5-MTHF is effective for the correction of hyperhomocysteinemia. <i>Nutrition Research</i> , 2015, 35, 489-495.	2.9	8
38	Can echocardiography improve the prediction of thromboembolic risk in atrial fibrillation? Evidences and perspectives. <i>Internal and Emergency Medicine</i> , 2020, 15, 935-943.	2.0	8
39	Cancer-Associated Splanchnic Vein Thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 931-941.	2.7	8
40	Budd-Chiari syndrome in a paroxysmal nocturnal hemoglobinuria patient with previous cerebral venous thrombosis. <i>Internal and Emergency Medicine</i> , 2009, 4, 75-77.	2.0	7
41	Impact of cardiovascular and immunologic variables on subclinical carotid atherosclerosis in subjects with anti-phospholipid antibodies. <i>Data in Brief</i> , 2018, 19, 1799-1803.	1.0	7
42	Sustained High D-Dimer in Outpatients Who Have Recovered from Mild to Moderate Coronavirus Disease 2019 (COVID-19). <i>Seminars in Thrombosis and Hemostasis</i> , 2021, , .	2.7	7
43	Atrial cardiomyopathy: Pathophysiology and clinical implications. <i>European Journal of Internal Medicine</i> , 2022, 101, 29-31.	2.2	7
44	Systemic Catheter-Related Venous Thromboembolism in Children: Data From the Italian Registry of Pediatric Thrombosis. <i>Frontiers in Pediatrics</i> , 2022, 10, 843643.	1.9	7
45	Clinical Differences between COVID-19 and a COVID-Like Syndrome. <i>Journal of Clinical Medicine</i> , 2021, 10, 2519.	2.4	6
46	The Growing Impact of Cardiovascular Oncology: Epidemiology and Pathophysiology. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 899-906.	2.7	6
47	Hypocalcemia and hypophosphatemia after treatment with zoledronic acid in a patient with AL amyloidosis. <i>Internal and Emergency Medicine</i> , 2019, 14, 447-449.	2.0	5
48	The HLA Variant rs6903608 Is Associated with Disease Onset and Relapse of Immune-Mediated Thrombotic Thrombocytopenic Purpura in Caucasians. <i>Journal of Clinical Medicine</i> , 2020, 9, 3379.	2.4	5
49	Acquired Factor V Inhibitor after Coronavirus Disease 2019 (COVID-19). <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 124-126.	2.7	5
50	Atrial fibrillation, cancer and echocardiography. <i>Journal of Cardiovascular Echography</i> , 2020, 30, 33.	0.4	5
51	The Challenge of Diagnosing Pulmonary Embolism in Children, Pregnant Women, and Elderly Patients: A Descriptive Review of the Literature. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 908-917.	2.7	4
52	Outcomes after venous thromboembolism in patients with gastric cancer: Analysis of the RIETE Registry. <i>Vascular Medicine</i> , 2020, 25, 210-217.	1.5	4
53	Cardiovascular disease and antiphospholipid syndrome: how to predict and how to treat?. <i>Polish Archives of Internal Medicine</i> , 2020, 131, 161-170.	0.4	4
54	Current and evolving features in the clinical management of haemophilia. <i>Blood Transfusion</i> , 2014, 12 Suppl 3, s554-62.	0.4	4

#	ARTICLE	IF	CITATIONS
55	Cytomegalovirus-Associated Splanchnic Vein Thrombosis in Immunocompetent Patients: Two Case Reports and Literature Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 298-303.	2.7	3
56	Phenotyping of CYP 4501A2 Activity by Total Overnight Salivary Caffeine Assessment (TOSCA) in Patients on Warfarin Treatment: A Cross-Sectional Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 928-935.	1.7	3
57	Evaluation of the SAME-TT2R2 score to predict the quality of anticoagulation control in patients with venous thromboembolism treated with vitamin K antagonists: Findings from the RIETE registry. <i>Thrombosis Research</i> , 2020, 194, 178-182.	1.7	3
58	Management of bleeding in acquired haemophilia A with recombinant activated factor VII: does one size fit all? A report of four cases. <i>Blood Transfusion</i> , 2015, 13, 328-32.	0.4	3
59	The role of cardiovascular ultrasound in diagnosis and management of pulmonary embolism. <i>Future Cardiology</i> , 2017, 13, 465-477.	1.2	2
60	Prophylaxis of venous thromboembolism in Internal Medicine Units: the RAMs issue. <i>Internal and Emergency Medicine</i> , 2018, 13, 463-465.	2.0	2
61	Arterial Thrombosis in Cancer Patients: An Update. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 942-949.	2.7	2
62	The "antiphospholipid triangle" in an asymptomatic patient: a case report. <i>Internal and Emergency Medicine</i> , 2010, 5, 457-458.	2.0	1
63	Prevention of relapse in patients with acquired thrombotic thrombocytopenic purpura undergoing elective surgery: a case series. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 492-498.	3.8	1
64	Cardiovascular and Thromboembolic Diseases in Oncology: Novel Aspects and Revisited Issues. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 896-898.	2.7	1
65	Role of New Potential Biomarkers in the Risk of Thromboembolism in Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2022, 11, 915.	2.4	1
66	Comparison of Full-Dose vs Moderate-Dose Systemic Thrombolysis for the Treatment of Patients With Acute Pulmonary Embolism. <i>Chest</i> , 2022, 162, 448-451.	0.8	1
67	Optimizing antithrombotic therapy for atrial fibrillation in cancer. <i>Thrombosis Research</i> , 2022, 213, S103-S106.	1.7	1
68	The "every rare" unusual sites venous thromboses. <i>Internal and Emergency Medicine</i> , 2017, 12, 745-747.	2.0	0
69	Cardiovascular and Thromboembolic Diseases in Oncology: Novel Aspects and Revisited Issues. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 895-895.	2.7	0